Oral Small Molecule Therapeutics
•249 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (249)
%
| Company | Market Cap | Price |
|---|---|---|
|
ORLYNVAH is an oral small-molecule therapeutic antibiotic (sulopenem etzadroxil-probenecid).
|
$29.68M |
$0.74
-9.52%
|
|
Cadrenal's lead candidate tecarfarin is an oral small molecule anticoagulant, aligning with the Orals Small Molecule Therapeutics tag.
|
$27.59M |
$14.03
+0.14%
|
|
Lead and prioritized programs consist of oral small molecule therapeutics (e.g., CHK1 inhibitor BBI-355, RNR inhibitor BBI-825, kinesin degrader BBI-940).
|
$27.53M |
$1.23
-0.81%
|
|
Direct sale/distribution of oral small-molecule therapeutics (e.g., testosterone therapy).
|
$24.27M |
$2.20
-4.76%
|
|
Ketamir-2, MIRA-55, and SKNY-1 are all oral small-molecule therapeutics in the company's core pipeline.
|
$21.32M |
$1.26
-6.67%
|
|
Lead programs are oral small-molecule therapeutics (vebreltinib and apolecylin).
|
$20.27M |
$18.43
|
|
KROS 101 is an orally available small-molecule therapeutic (Oral Small Molecule Therapeutics).
|
$19.55M |
$1.16
-12.12%
|
|
Elite's product lines are primarily oral, small-molecule therapeutics including CNS stimulants and other generics.
|
$18.36M |
$0.63
+0.13%
|
|
X4's lead product mavorixafor is an oral small-molecule therapeutic for rare immunodeficiency conditions (WHIM CN).
|
$17.89M |
$3.09
-6.36%
|
|
Phyto-N is a botanical drug candidate likely intended for oral administration in inflammatory diseases, aligning with Oral Small Molecule Therapeutics.
|
$16.76M |
$0.70
-6.82%
|
|
Ratutrelvir and tivoxavir marboxil are oral small-molecule therapeutics, with tivoxavir described as a single-dose influenza therapy.
|
$16.75M |
$3.01
-2.27%
|
|
Roluperidone is a small-molecule therapeutic likely delivered orally as monotherapy.
|
$16.43M |
$2.35
-2.89%
|
|
Emavusertib is an oral small-molecule therapeutic, aligning with the major product category of Oral Small Molecule Therapeutics.
|
$15.90M |
$1.52
-6.17%
|
|
BXCL501 is an oral small molecule therapeutic (sublingual film) for acute agitation, aligning with Oral Small Molecule Therapeutics.
|
$15.32M |
$2.53
-3.80%
|
|
TLANDO and pipeline candidates are formulated as oral small‑molecule therapeutics, aligning with the tag.
|
$14.61M |
$2.73
-1.80%
|
|
ADHD medications Adzenys XR-ODT and Cotempla XR-ODT are small-molecule therapeutics delivered orally.
|
$14.56M |
$2.36
-7.45%
|
|
In-house development of oral small-molecule therapeutics (e.g., Mebendazole formulations) aligns with Oral Small Molecule Therapeutics.
|
$13.56M |
$1.44
-4.64%
|
|
Lead and pipeline candidates are designed for oral administration, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$11.70M |
$1.15
-7.26%
|
|
IHL-42X and the firm’s other pipeline assets are delivered as oral small-molecule therapeutics (oral drugs).
|
$11.53M |
$0.39
-9.33%
|
|
PALI-2108 is an orally administered small-molecule therapeutic, fitting the Oral Small Molecule Therapeutics category.
|
$9.59M |
$2.00
-3.38%
|
|
Arbli is an oral liquid formulation of a small molecule antihypertensive (losartan), representing an oral small molecule therapeutic pipeline.
|
$9.20M |
$0.70
-6.52%
|
|
ALS-4 is a repurposed small-molecule therapeutic in Phase 1, representing Oral Small Molecule Therapeutics activity.
|
$9.08M |
$1.66
-30.83%
|
|
Ib ezapolstat is an oral small-molecule antibiotic, forming the core product in Acurx's pipeline.
|
$8.78M |
$7.48
+10.49%
|
|
TH104 is a nalmefene small-molecule delivered via transmucosal buccal film (oral small molecule therapeutics).
|
$7.93M |
$2.98
-7.45%
|
|
Lead products APR-1051 and ATRN-119.00 are oral small-molecule therapeutics.
|
$7.85M |
$1.42
-5.33%
|
|
Development of oral small molecule therapeutics (MC-1 and NCEs) aligns with the Oral Small Molecule Therapeutics category.
|
$7.83M |
$0.75
|
|
Linebacker/Equivir are small-molecule therapeutics (oral) platforms; categorize under Oral Small Molecule Therapeutics.
|
$7.69M |
$0.64
+0.47%
|
|
core offerings are small-molecule therapeutics (GABAB PAMs, mGluR5 NAM) delivered as oral drugs, aligning with Oral Small Molecule Therapeutics.
|
$7.43M |
$9.44
+7.49%
|
|
SBFM-PL4 is reported as orally active in preclinical models, aligning with the oral small-molecule therapeutics category.
|
$7.06M |
$1.55
-6.63%
|
|
Gimoti is a nasally administered small-molecule metoclopramide product that Evoke Pharma directly commercializes, representing its core pharmaceutical product line.
|
$6.82M |
$4.57
-0.41%
|
|
AL001 is an oral small molecule therapeutic (lithium formulation) intended for brain health in neuropsychiatric/neurodegenerative conditions.
|
$6.31M |
$2.18
-5.63%
|
|
PAS-4.00 is described as an oral small-molecule therapeutic (capsules/tablets) with once-daily dosing.
|
$5.58M |
$0.75
-3.55%
|
|
VYN202 is an oral BD2-selective small-molecule therapeutic, aligning with Oral Small Molecule Therapeutics.
|
$5.53M |
$0.33
+5.00%
|
|
CMND-100 is an oral small-molecule therapeutic candidate, indicating focus on oral small molecule therapies.
|
$3.70M |
$0.93
-5.00%
|
|
Bezisterim (NE3107) is an orally administered small molecule therapeutic targeting inflammation-driven insulin resistance in neurodegenerative diseases, matching the Orals Small Molecule Therapeutics category.
|
$3.40M |
$1.83
-8.50%
|
|
AD04 is an oral small molecule therapeutic targeting Alcohol Use Disorder (AUD).
|
$3.15M |
$0.39
-3.34%
|
|
Lucemyra is an FDA-approved oral small-molecule therapeutic distributed by BioCorRx, aligning with the 'Oral Small Molecule Therapeutics' investable category.
|
$2.98M |
$0.45
|
|
Lead candidates Piclidenoson and Namodenoson are orally bioavailable small-molecule therapeutics.
|
$2.66M |
$0.53
-7.02%
|
|
The NGC portfolio includes small-molecule therapeutics (with oral components such as NGC-Cap) classifying the program under Oral Small Molecule Therapeutics.
|
$2.53M |
$0.21
+10.59%
|
|
Crofelemer and NP-300 are oral small molecule anti-secretory agents, aligning with the Oral Small Molecule Therapeutics category.
|
$2.11M |
$2.07
-5.91%
|
|
Direct product category: Mazindol extended-release formulations developed as oral small molecule therapeutics (Quilience, Nolazol) for CNS disorders.
|
$1.73M |
$1.76
-4.35%
|
|
The company develops small molecule therapeutics (neuroplastogens) as its core drug candidates.
|
$1.71M |
$0.68
-1.76%
|
|
Lead and pipeline include oral small-molecule therapeutics used in cancer therapy.
|
$1.67M |
$3.80
+6.74%
|
|
LP-310 is an oral liposomal tacrolimus formulation (an oral small molecule) representing a direct Oral Small Molecule Therapeutics offering.
|
$1.63M |
$0.64
+16.28%
|
|
Lead NOS inhibitor is a small molecule therapeutic candidate, aligning with the Oral Small Molecule Therapeutics category.
|
$979059 |
$0.02
|
|
Lead assets are oral small-molecule therapeutics (cancer targets), aligning with the Oral Small Molecule Therapeutics category.
|
$557349 |
$3.93
+0.51%
|
|
AZD1656/AZD5658 are oral small-molecule therapeutics; CDT Equity's lead assets are repositioned pharmacological compounds.
|
$391060 |
$0.49
-7.89%
|
|
Endari is an oral small-molecule therapeutic (L-glutamine) used to treat sickle cell disease, representing Emmaus's core product category.
|
$20252 |
$0.01
-3.83%
|
|
NUC-3373 and NUC-7738 are small-molecule nucleoside analog derivatives developed for cancer therapy, aligning with the Oral Small Molecule Therapeutics category.
|
N/A |
$5.33
-10.72%
|
Showing page 3 of 3 (249 total stocks)
Loading industry metrics...
Loading comparison data...
